Equillium Inc (EQ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Equillium Inc stock (EQ) is currently trading at $1.95. Equillium Inc PS ratio (Price-to-Sales) is 29.53. Analyst consensus price target for EQ is $5.50. WallStSmart rates EQ as Sell.
- EQ PE ratio analysis and historical PE chart
- EQ PS ratio (Price-to-Sales) history and trend
- EQ intrinsic value — DCF, Graham Number, EPV models
- EQ stock price prediction 2025 2026 2027 2028 2029 2030
- EQ fair value vs current price
- EQ insider transactions and insider buying
- Is EQ undervalued or overvalued?
- Equillium Inc financial analysis — revenue, earnings, cash flow
- EQ Piotroski F-Score and Altman Z-Score
- EQ analyst price target and Smart Rating
Equillium Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Equillium Inc (EQ) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Equillium Inc (EQ) Key Strengths (1)
58.11% held by institutions, strong professional interest
Supporting Valuation Data
Equillium Inc (EQ) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -52.30%, a shrinking business
Very expensive at 29.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.2x book value
Supporting Valuation Data
Equillium Inc (EQ) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (29.53), Price/Book (4.20) suggest expensive pricing. Growth concerns include Revenue Growth at -52.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -90.20%, Operating Margin at -555.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -90.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -52.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EQ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EQ's Price-to-Sales ratio of 29.53x trades 383% above its historical average of 6.11x (93th percentile), historically expensive. The current valuation is 14% below its historical high of 34.25x set in Mar 2026, and 6320% above its historical low of 0.46x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~0.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Equillium Inc (EQ) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Equillium Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 4M with 52% decline year-over-year.
Key Findings
Spending 30% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 52% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -8M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.83, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Equillium Inc.
Bottom Line
Equillium Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Equillium Inc(EQ)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.